A prescription cardiovascular medication called CLOPIGOLD A 150 contains 75 mg of clopidogrel and 150 mg of aspirin in a single capsule. For antiplatelet control, this combination medication is frequently used to help patients at risk of cardiovascular and cerebrovascular events avoid blood clot formation.

By preventing platelet aggregation, clopidogrel and aspirin operate in concert to lower the risk of heart attack, stroke, and other thrombotic consequences. Patients who have unstable angina, acute coronary syndrome (ACS), or have undergone percutaneous coronary interventions (PCI) with stent implantation may benefit most from CLOPIGOLD A 150.

A single capsule containing two powerful antiplatelet drugs guarantees efficient and practical treatment, enhancing adherence and clinical results. Cardiologists trust CLOPIGOLD A 150 because of its shown effectiveness.

Uses

CLOPIGOLD A 150 is indicated for the prevention and management of thrombotic cardiovascular events in high-risk patients. Its primary uses include:

1. Acute Coronary Syndrome (ACS)

The combination of Clopidogrel and Aspirin reduces the risk of heart attacks and complications in patients experiencing unstable angina or myocardial infarction.

2. Post-Percutaneous Coronary Intervention (PCI)

CLOPIGOLD A 150 is prescribed after stent placement to prevent stent thrombosis, ensuring long-term patency of the coronary arteries.

3. Secondary Prevention of Cardiovascular Events

Patients with a history of myocardial infarction, stroke, or peripheral arterial disease benefit from this dual antiplatelet therapy to lower the risk of recurrent events.

4. High-Risk Thrombotic Patients

It is useful for individuals with multiple risk factors such as diabetes, hypertension, and hyperlipidemia, where the likelihood of clot formation is elevated.

By inhibiting platelet aggregation through two different pathways, CLOPIGOLD A 150 provides comprehensive protection against clot-related complications.

Benefits

CLOPIGOLD A 150 offers multiple clinical and patient-centric benefits:

1. Dual Mechanism of Action

Clopidogrel inhibits ADP-induced platelet aggregation, while Aspirin irreversibly inhibits cyclooxygenase (COX-1), reducing thromboxane A2 synthesis. Together, they provide enhanced antiplatelet efficacy.

2. Prevention of Heart Attacks and Stroke

Regular therapy significantly lowers the risk of myocardial infarction, ischemic stroke, and systemic embolism, particularly in high-risk cardiovascular patients.

3. Improved Post-Stent Outcomes

The combination reduces the likelihood of stent thrombosis, improving long-term success rates of PCI procedures.

4. Convenient Single-Capsule Therapy

Combining two drugs in a single capsule simplifies treatment, enhances patient compliance, and reduces the chances of missed doses.

5. Evidence-Based Clinical Efficacy

Numerous clinical studies have confirmed that dual antiplatelet therapy (DAPT) with Clopidogrel and Aspirin is more effective than single-agent therapy in preventing recurrent thrombotic events.

6. Long-Term Cardiovascular Protection

CLOPIGOLD A 150 can be incorporated into long-term management plans for patients with a history of ACS or cerebrovascular disease, contributing to improved prognosis and reduced hospitalization rates.

These advantages make CLOPIGOLD A 150 a cornerstone therapy in cardiology and preventive cardiovascular care.

Dosage

The dosage of CLOPIGOLD A 150 must be tailored by a healthcare professional based on the patient’s cardiovascular risk profile and clinical condition.

Recommended Dosage:

• Typical Dose: One capsule of CLOPIGOLD A 150 mg once daily, preferably taken at the same time each day.

• Administration: Capsules should be swallowed whole with water. Do not crush or chew the capsule, as this may affect drug release and efficacy.

• With or Without Food: Can be taken with or without food, but taking it consistently with meals may reduce gastrointestinal discomfort.

Special Considerations:

• Duration of therapy is usually determined by clinical indication, such as post-PCI stent placement or ACS management.

• In patients with bleeding risk or renal/hepatic impairment, the dosage and treatment duration should be carefully evaluated.

• Therapy should not be discontinued abruptly without consulting a doctor, as this can increase the risk of thrombotic events.

Proper adherence to the prescribed regimen ensures optimal cardiovascular protection.

Side Effects

While CLOPIGOLD A 150 is generally well-tolerated, some patients may experience side effects, mostly related to the antiplatelet action.

Common Side Effects:

• Gastrointestinal discomfort or heartburn

• Mild nausea or vomiting

• Headache

• Easy bruising

Less Common but Serious Side Effects:

• Gastrointestinal bleeding or ulcers

• Severe or unexplained bruising

• Hemorrhagic stroke or intracranial bleeding

• Allergic reactions, including rash, itching, or swelling

Important Note:

Patients should immediately report signs of excessive bleeding, such as blood in stool or urine, prolonged bleeding from cuts, or persistent nosebleeds. Early detection allows timely intervention and minimizes complications.

Precautions and Warning

Before initiating therapy with CLOPIGOLD A 150, several precautions must be considered:

1. Bleeding Risk

Patients with a history of bleeding disorders, gastrointestinal ulcers, or hemorrhagic stroke should use this medication with caution.

2. Surgical Procedures

Inform the doctor before any planned surgery or dental procedure, as temporary discontinuation may be required to reduce bleeding risk.

3. Drug Interactions

CLOPIGOLD A 150 can interact with other medications, including anticoagulants, NSAIDs, corticosteroids, and herbal supplements. Always inform the physician of all concurrent drugs.

4. Pregnancy and Breastfeeding

Use during pregnancy or lactation only if clearly indicated and prescribed by a healthcare professional.

5. Kidney and Liver Function

Dose adjustment or monitoring may be necessary in patients with renal or hepatic impairment.

6. Avoid Abrupt Discontinuation

Stopping therapy suddenly can increase the risk of thrombotic events, particularly after stent placement or ACS. Always consult a doctor before discontinuation.

Adhering to these precautions ensures maximum safety and therapeutic effectiveness.

Conclusion

CLOPIGOLD A 150, combining Clopidogrel 75 mg and Aspirin 150 mg, is a clinically proven dual antiplatelet therapy designed to reduce the risk of heart attacks, strokes, and other thrombotic events in high-risk cardiovascular patients.